In order to further characterize the effect of EIF4G2 protein depletion on cancer outcome, and to understand why EIF4G2KD cells are more resistant to therapies, we examined the prevalence of aggressive sub-populations within the control and EIF4G2KD cells by probing for CD133 (PROM1) and CD44. Here, EIF4G2 is linked to cancer.